NSPR huge undervalued. Zero Debt and $7m+ cash - Strongly growing sales Between 77% - 132% last qtr -Products soon to launch in many countries where approved + application to US FDA. http://www.inspiremd.com/en/wp-content/uploads/NSPR-Corporate-Presentation-Feb.-2018-1.pdf